Moderna, Inc. (MRNA)
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna to apply for approval of its standalone flu vaccine, called mRNA-1010, later this year.
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.
Moderna (MRNA) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Moderna (MRNA) closed at $25.90, indicating a +1.97% shift from the previous trading day.
Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript
Moderna, Inc. (NASDAQ:MRNA ) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ET Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Rose Loughlin - Executive Vice President of Research Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Huidong Wang My name is Gena Wang. I'm SMID Cap biotech analyst at the Barclays.
Here's Why Moderna (MRNA) Fell More Than Broader Market
Moderna (MRNA) closed the most recent trading day at $26.68, moving 2.45% from the previous trading session.
Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great. Good morning, everyone.
What Sparked Moderna Stock Crash?
Moderna's stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the European Union renegotiated its vaccine supply agreement with Pfizer and BioNTech.
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference Transcript
Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Hi, everyone. Thank you.
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
Moderna, favored by the first Trump administration for its Covid-19 vaccine, is now in trouble as Trump 2.0 shifts its position on vaccine-making
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful
Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost-cutting, pipeline focus, and realistic revenue guidance after overreaching post-pandemic and burning through cash on speculative projects. Despite leadership changes at HHS and FDA and loss of government funding, Moderna could outperform 2025 guidance if vaccination rates and combo shots gain traction.
